| Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression. | sarcoma, |
| The fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype when expressed in a primitive sarcoma cell line. | sarcoma, |
| The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells. | fibrosarcoma, |
| FUS-DDIT3 is a chimeric oncogene generated by the most common chromosomal translocation t(12;16)(q13;p11) associated to liposarcomas. | sarcoma, |
| Fat-specific FUS-DDIT3-transgenic mice establish PPARgamma inactivation is required to liposarcoma development. | sarcoma, |
| DDIT3/CHOP and the sarcoma fusion oncoprotein FUS-DDIT3/TLS-CHOP bind cyclin-dependent kinase 2. | sarcoma, |
| A mechanistic study on the metastasis inducing function of FUS-CHOP fusion protein in liposarcoma. | sarcoma, |
| Thus, further investigation of the pro- and antioncogenic functions of CHOP is likely to reveal important new insights into the pathogenesis of liver cancer and other tumor types | liver, |
| The herein presented data uncover a novel mechanism by which the fusion oncogene FUS-CHOP actively promotes invasion in myxoid and round cell liposarcoma through the activation of a SRC/FAK/RHO/ROCK signaling axis. | sarcoma, |
| Fusion of the EWS and CHOP genes in myxoid liposarcoma. | sarcoma, |
| Human translocation liposarcoma-CCAAT/enhancer binding protein (C/EBP) homologous protein (TLS-CHOP) oncoprotein prevents adipocyte differentiation by directly interfering with C/EBPbeta function. | sarcoma, |
| oncogenic Ras-mediated cellular transformation also involves downmodulation of important molecules such as Gadd153 that negatively regulate cell growth and survival | None |